MedTrace Logo

Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood

NCT00125047 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27231

Last updated 2008-08-26

No results posted yet for this study

Summary

This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Karachi, Pakistan. The cost-effectiveness of Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.

Conditions

  • Typhoid
  • Paratyphoid Fever

Interventions

BIOLOGICAL

Typhoid Vi vaccine

Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.

BIOLOGICAL

Hepatitis A vaccine

single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen

Sponsors & Collaborators

  • Aga Khan University

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • University of Western Ontario, Canada

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Zulfiqar A Bhutta, MBBS, PhD · Aga Khan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125047 on ClinicalTrials.gov